Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
iBio, Inc. announced an exclusive agreement with AstralBio to license a long-acting anti-myostatin antibody, IBIO-600, designed for obesity and cardiometabolic disorders. This agreement involves ...
4536.T Santen Pharmaceutical Co., Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback